DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

IOL Chemicals and Pharmaceuticals Limited — Key licenses/regulatory approvals (Sub-para 12-Para B)

NSE 52 min ago·23 Sept 2026, 10:43 am

IOL Chem AND Pharma

IOL Chemicals and Pharmaceuticals Limited has informed stock exchanges about the receipt of certain key licenses and regulatory approvals. This update relates to a specific clause (Sub-para 12-Para B) and indicates that the company has successfully navigated a required compliance process. The company has filed this disclosure to ensure transparency regarding its regulatory standing.

For investors, this news is generally viewed as a positive development. Securing these approvals is a critical step for the company's operations, as it confirms that it meets the necessary legal and safety standards. This can help reduce operational uncertainty and may support the company's ability to continue its business activities and future growth plans.

Investors should monitor the company's future announcements to see how these approvals impact its production capacity and financial performance. Keeping an eye on the broader market sentiment regarding the pharma sector will also be important as the stock reacts to this regulatory milestone.